AI assistant
BIOMARIN PHARMACEUTICAL INC — Director's Dealing 2019
Mar 6, 2019
30583_dirs_2019-03-05_58c85887-4865-4bac-a57c-1d79c427bcb4.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIOMARIN PHARMACEUTICAL INC (BMRN)
CIK: 0001048477
Period of Report: 2019-03-01
Reporting Person: FUCHS HENRY J (President, Worldwide R&D)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-03-01 | Common Stock | A | 15687 | — | Acquired | 145854 | Direct |
| 2019-03-01 | Common Stock | F | 1154 | $94.76 | Disposed | 144700 | Direct |
Footnotes
F1: Transaction Date is the date that the Issuer's Board of Directors' Compensation Committee Chair certified that the reporting person earned the Restricted Stock Units (RSUs), which are convertible into shares of the Issuer's Common Stock on a 1:1 basis.
F2: Represents the total number of RSUs earned pursuant to a calculation set forth in the performance-based RSU awards previously granted under the Issuer's 2017 Equity Incentive Plan based on the level of the Issuer's total adjusted net product revenues for the fiscal year ended December 31, 2018 as set forth in the Issuer's audited financial statements.
F3: Although earned, the RSUs only vest according to the following schedule: 1/3 vests on each of March 15, 2019, 2020 and 2021, so long as the reporting person remains continuously employed with the Issuer through that date, subject to earlier vesting upon certain events.